Implantable anti-angiogenic scaffolds for treatment of neovascular ocular pathologies

Biplab Sarkar; Zain Siddiqui; Ka Kyung Kim; Peter K. Nguyen; Xavier Reyes; Trevor J. McGill; Vivek A. Kumar

doi:10.1007/s13346-020-00753-0

Implantable anti-angiogenic scaffolds for treatment of neovascular ocular pathologies

Biplab Sarkar, Zain Siddiqui, Ka Kyung Kim, Peter K. Nguyen, Xavier Reyes, Trevor J. McGill, Vivek A. Kumar

Bio-Medical Engineering

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

The retinal physiology can accrue oxidative damage and inflammatory insults due to age and metabolic irregularities. Two notable diseases that involve retinal and choroidal neovascularization are proliferative diabetic retinopathy and wet age-related macular degeneration. Currently, these diseases are mainly treated with anti-VEGF drugs (VEGF = vascular endothelial growth factor), generally on a monthly dosage scheme. We discuss recent developments for the treatment of these diseases, including bioactive tissue-engineered materials, which may reduce frequency of dosage and propose a path forward for improving patient outcomes. [Figure not available: see fulltext.]

Original language	English (US)
Pages (from-to)	1191-1202
Number of pages	12
Journal	Drug Delivery and Translational Research
Volume	10
Issue number	5
DOIs	https://doi.org/10.1007/s13346-020-00753-0
State	Published - Oct 1 2020

All Science Journal Classification (ASJC) codes

Pharmaceutical Science

Keywords

Age-related macular degeneration
Anti-angiogenic materials
Diabetic retinopathy
Hydrogel
Pathological neovascularization
Peptide nanofibers
Self-assembly

Access to Document

10.1007/s13346-020-00753-0

Cite this

@article{cdcdac84b1da4d39a162a213e9b2daba,

title = "Implantable anti-angiogenic scaffolds for treatment of neovascular ocular pathologies",

abstract = "The retinal physiology can accrue oxidative damage and inflammatory insults due to age and metabolic irregularities. Two notable diseases that involve retinal and choroidal neovascularization are proliferative diabetic retinopathy and wet age-related macular degeneration. Currently, these diseases are mainly treated with anti-VEGF drugs (VEGF = vascular endothelial growth factor), generally on a monthly dosage scheme. We discuss recent developments for the treatment of these diseases, including bioactive tissue-engineered materials, which may reduce frequency of dosage and propose a path forward for improving patient outcomes. [Figure not available: see fulltext.]",

keywords = "Age-related macular degeneration, Anti-angiogenic materials, Diabetic retinopathy, Hydrogel, Pathological neovascularization, Peptide nanofibers, Self-assembly",

author = "Biplab Sarkar and Zain Siddiqui and Kim, {Ka Kyung} and Nguyen, {Peter K.} and Xavier Reyes and McGill, {Trevor J.} and Kumar, {Vivek A.}",

note = "Publisher Copyright: {\textcopyright} 2020, Controlled Release Society.",

year = "2020",

month = oct,

day = "1",

doi = "10.1007/s13346-020-00753-0",

language = "English (US)",

volume = "10",

pages = "1191--1202",

journal = "Drug Delivery and Translational Research",

issn = "2190-393X",

publisher = "Springer Publishing Company",

number = "5",

}

TY - JOUR

T1 - Implantable anti-angiogenic scaffolds for treatment of neovascular ocular pathologies

AU - Sarkar, Biplab

AU - Siddiqui, Zain

AU - Kim, Ka Kyung

AU - Nguyen, Peter K.

AU - Reyes, Xavier

AU - McGill, Trevor J.

AU - Kumar, Vivek A.

PY - 2020/10/1

Y1 - 2020/10/1

N2 - The retinal physiology can accrue oxidative damage and inflammatory insults due to age and metabolic irregularities. Two notable diseases that involve retinal and choroidal neovascularization are proliferative diabetic retinopathy and wet age-related macular degeneration. Currently, these diseases are mainly treated with anti-VEGF drugs (VEGF = vascular endothelial growth factor), generally on a monthly dosage scheme. We discuss recent developments for the treatment of these diseases, including bioactive tissue-engineered materials, which may reduce frequency of dosage and propose a path forward for improving patient outcomes. [Figure not available: see fulltext.]

AB - The retinal physiology can accrue oxidative damage and inflammatory insults due to age and metabolic irregularities. Two notable diseases that involve retinal and choroidal neovascularization are proliferative diabetic retinopathy and wet age-related macular degeneration. Currently, these diseases are mainly treated with anti-VEGF drugs (VEGF = vascular endothelial growth factor), generally on a monthly dosage scheme. We discuss recent developments for the treatment of these diseases, including bioactive tissue-engineered materials, which may reduce frequency of dosage and propose a path forward for improving patient outcomes. [Figure not available: see fulltext.]

KW - Age-related macular degeneration

KW - Anti-angiogenic materials

KW - Diabetic retinopathy

KW - Hydrogel

KW - Pathological neovascularization

KW - Peptide nanofibers

KW - Self-assembly

UR - http://www.scopus.com/inward/record.url?scp=85083099767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083099767&partnerID=8YFLogxK

U2 - 10.1007/s13346-020-00753-0

DO - 10.1007/s13346-020-00753-0

M3 - Review article

C2 - 32232681

AN - SCOPUS:85083099767

SN - 2190-393X

VL - 10

SP - 1191

EP - 1202

JO - Drug Delivery and Translational Research

JF - Drug Delivery and Translational Research

IS - 5

ER -

Implantable anti-angiogenic scaffolds for treatment of neovascular ocular pathologies

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this